Baird 'Incrementally Negative' After Celgene (CELG) GED-0301 Data a Non-Event

September 12, 2016 11:02 AM EDT
Get Alerts CELG Hot Sheet
Price: $98.91 --0%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 27 | New: 31
Trade CELG Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst Brian Skorney said he is incrementally negative after Celgene (NASDAQ: CELG) on GED_0301 results. The firm, however, maintained a Outperform rating and price target of $162.00.

Skorney commented, "Celgene's big 2H16 catalyst turned out to be a non-event, as the topline results of the GED-0301 endoscopy study didn’t include any results. Management is claiming the standard: “We’re reserving data for a medical conference” line, but it’s hard to believe an unambiguous success wouldn’t be described in some quantitative detail."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $104.47 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Robert W Baird

Add Your Comment